Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Furosemide

FDA-approved product (tablet, oral), marketed as Furoscix, Furoscix Readyflow (Autoinjector), Furosemide and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Furosemide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Pulmonary edema
  • Syndromic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Loop Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Furosemide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Furosemide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Using Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates

    NCT00618852 · start 2007-01

    Registered record
    Registry ID
    NCT00618852
    Conditions
    Lung Disease
    Interventions
    Furosemide; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2007-01
    Completion
    2009-06
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Disease
    InterventionFurosemide; Saline
    PhasePhase 3
    Registry statusUnknown

  • Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

    NCT00551122 · start 2006-11

    Registered record
    Registry ID
    NCT00551122
    Conditions
    Brain and Central Nervous System Tumors; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
    Interventions
    filgrastim; lenograstim; pegfilgrastim; cisplatin; gemcitabine hydrochloride; ifosfamide; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2006-11
    Completion
    Not recorded
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
    Interventionfilgrastim; lenograstim; pegfilgrastim; cisplatin +3 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure

    NCT00355667 · start 2006-06

    Registered record
    Registry ID
    NCT00355667
    Conditions
    Congestive Heart Failure
    Interventions
    furosemide; azosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-06
    Completion
    2010-08
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongestive Heart Failure
    Interventionfurosemide; azosemide
    PhasePhase 4
    Registry statusCompleted

  • Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients

    NCT00249067 · start 2005-10

    Registered record
    Registry ID
    NCT00249067
    Conditions
    Heart Failure; Heart Murmurs
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2005-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Murmurs
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study

    NCT00421863 · start 2005-02

    Registered record
    Registry ID
    NCT00421863
    Conditions
    Hypertension
    Interventions
    Triatec 10 mg; Triatec HCT 5; Lasix 25; Micardis 80 mg; Micardis plus 80/12.5; Catapresan TTS 2; Norvasc 10 mg; Triatec 5 mg; Pluscor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-02
    Completion
    2009-01
    Enrolment
    1,111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTriatec 10 mg; Triatec HCT 5; Lasix 25; Micardis 80 mg +5 more
    PhasePhase 4
    Registry statusCompleted